Long‐term Results Comparing Cervical Disc Arthroplasty to Anterior Cervical Discectomy and Fusion: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials

  • Qiao‐li Wang
    ICU Center The Second Xiangya Hospital of Central South University Changsha China
  • Zhi‐ming Tu
    Department of Spine Surgery The Second Xiangya Hospital of Central South University Changsha China
  • Pan Hu
    Department of Surgery Massachusetts General Hospital, Harvard Medical School Boston Massachusetts USA
  • Filippos Kontos
    Department of Surgery Massachusetts General Hospital, Harvard Medical School Boston Massachusetts USA
  • Ya‐wei Li
    Department of Spine Surgery The Second Xiangya Hospital of Central South University Changsha China
  • Lei Li
    Department of Spine Surgery The Second Xiangya Hospital of Central South University Changsha China
  • Yu‐liang Dai
    Department of Spine Surgery The Second Xiangya Hospital of Central South University Changsha China
  • Guo‐hua Lv
    Department of Spine Surgery The Second Xiangya Hospital of Central South University Changsha China
  • Bing Wang
    Department of Spine Surgery The Second Xiangya Hospital of Central South University Changsha China

説明

<jats:sec><jats:title>Objective</jats:title><jats:p>Whether cervical disc arthroplasty (CDA) is superior to anterior cervical discectomy and fusion (ACDF) remains controversial, especially in relation to long‐term results. The present study aimed to evaluate the long‐term safety and efficiency of CDA and ACDF for cervical disc disease.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We performed this study according to the Cochrane methodology. An extensive search was undertaken in PubMed, Embase, and Cochrane databases up to 1 June 2019 using the following key words: “anterior cervical fusion,” “arthroplasty,” “replacement” and “artificial disc”. RevMan 5.3 (Cochrane, London, UK) was used to analyze data. Safety and efficiency outcome measures included the success rate, functional outcome measures, adverse events (AE), adjacent segment degeneration (ASD), secondary surgery, and patients’ satisfaction and recommendation rates. The OR and MD with 95% confidence interval (CI) were used to evaluate discontinuous and continuous variables, respectively. The statistically significant level was set at <jats:italic>P</jats:italic> < 0.05.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>A total of 11 randomized controlled trials with 3505 patients (CDA/ACDF: 1913/1592) were included in this meta‐analysis. Compared with ACDF, CDA achieved significantly higher overall success (2.10, 95% <jats:italic>CI</jats:italic> [1.70, 2.59]), neck disability index (NDI) success (1.73, 95% <jats:italic>CI</jats:italic> [1.37, 2.18]), neurological success (1.65, 95% <jats:italic>CI</jats:italic> [1.24, 2.20]), patients’ satisfaction (2.14, 95% <jats:italic>CI</jats:italic> [1.50, 3.05]), and patients’ recommendation rates (3.23, 95% <jats:italic>CI</jats:italic> [1.79, 5.80]). Functional outcome measures such as visual analog score neck pain (−5.50, 95% <jats:italic>CI</jats:italic> [−8.49, −2.52]) and arm pain (−3.78, 95% <jats:italic>CI</jats:italic> [−7.04, −0.53]), the Short Form‐36 physical component score (SF‐36 PCS) (1.93, 95% <jats:italic>CI</jats:italic> [0.53, 3.32]), and the Short Form‐36 mental component score (SF‐36 MCS) (2.62, 95% <jats:italic>CI</jats:italic> [0.95, 4.29]), revealed superiority in the CDA group. CDA also achieved a significantly lower rate of symptomatic ASD (0.46, 95% <jats:italic>CI</jats:italic> [0.34, 0.63]), total secondary surgery (0.50, 95% <jats:italic>CI</jats:italic> [0.29, 0.87]), secondary surgery at the index level (0.46, 95% <jats:italic>CI</jats:italic> [0.29, 0.74]), and secondary surgery at the adjacent level (0.37, 95% <jats:italic>CI</jats:italic> [0.28, 0.49]). However, no significant difference was found in radiological success (1.35, 95% <jats:italic>CI</jats:italic> [0.88, 2.08]), NDI score (−2.88, 95% <jats:italic>CI</jats:italic> [−5.93, 0.17]), total reported AE (1.14, 95% <jats:italic>CI</jats:italic> [0.92, 1.42]), serious AE (0.89, 95% <jats:italic>CI</jats:italic> [0.71, 1.11]), device/surgery‐related AE (0.90, 95% <jats:italic>CI</jats:italic> [0.68, 1.18]), radiological superior ASD (0.63, 95% <jats:italic>CI</jats:italic> [0.28, 1.43]), inferior ASD (0.45, 95% <jats:italic>CI</jats:italic> [0.19, 1.11]), and work status (1.33, 95% <jats:italic>CI</jats:italic> [0.78, 2.25]). Furthermore, subgroup analysis showed different results between US and non‐US groups.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Our study provided further evidence that compared to ACDF, CDA had a higher long‐term clinical success rate and better functional outcome measurements, and resulted in less symptomatic ASD and fewer secondary surgeries. However, worldwide multicenter RCT with long‐term follow up are still needed for further evaluation in the future.</jats:p></jats:sec>

収録刊行物

被引用文献 (2)*注記

もっと見る

問題の指摘

ページトップへ